Adrenal carcinoma
MONDO:0002814A carcinoma involving a adrenal gland.
Also known as: adrenal gland carcinoma, carcinoma of adrenal gland
2793 clinical trials for this condition and its sub-types, 34 tagged with Adrenal carcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Adrenal carcinoma
-
Adrenal cortex carcinoma 42 trials
1 sub-type
- Adrenocortical carcinoma, hereditary 0 trials
-
Adrenal medulla carcinoma 0 trials · 11 incl. sub-types
2 sub-types
-
New drug cocktail takes on rare adrenal cancer
Disease control Recruiting nowThis phase II trial tests whether adding the immunotherapy cemiplimab to the targeted drug cabozantinib works better than cabozantinib alone for advanced adrenocortical cancer. About 48 adolescents and adults whose cancer has spread or cannot be removed will take part. The study …
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New radiation approach before surgery for rare adrenal cancer
Disease control Recruiting nowThis early-phase trial tests giving radiation therapy before surgery to people whose adrenal cancer has come back. The goal is to find a safe radiation dose and see if it helps shrink tumors before removal. About 32 adults with resectable recurrent ACC will receive daily radiatio…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New hope for liver metastases: immune booster combined with targeted chemo
Disease control Recruiting nowThis study tests whether adding an immune-boosting drug (PDS01ADC) to standard chemotherapy delivered directly to the liver can help people with colorectal, bile duct, or adrenal cancer that has spread to the liver. About 70 adults will receive the drug combination along with a s…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New hope for rare cancers: experimental drug ADCT-701 enters human trials
Disease control Recruiting nowThis early-phase trial tests a new drug called ADCT-701 in adults with rare cancers like neuroendocrine tumors, adrenal cancer, and malignant peripheral nerve sheath tumors. The goal is to find the safest dose and see if it can shrink tumors or slow disease. Participants receive …
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Promising combo targets Hard-to-Treat childhood cancers
Disease control Recruiting nowThis study is testing a combination of two drugs—a targeted radioactive drug (177Lu-DOTATATE) and a PARP inhibitor (olaparib)—in children and teens aged 3 to 18 with certain solid tumors that have come back or not responded to treatment. The goal is to see if the combination is s…
Phase 1/2 • Sponsor: Fundación de investigación HM • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New pill takes on tough cancers in first human trial
Disease control Recruiting nowThis early-stage trial tests an oral drug called DS9051b in 40 people with advanced adrenocortical carcinoma or metastatic castration-resistant prostate cancer. The main goal is to check safety and find the right dose, while also looking for any signs that the drug might shrink t…
Phase 1 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Custom mRNA vaccine takes on rare endocrine cancers
Disease control Recruiting nowThis early study tests a personalized mRNA vaccine (mRNA-0523-L001) for people with advanced endocrine tumors like adrenal cancer, medullary thyroid cancer, and pancreatic neuroendocrine tumors who have no standard treatment left. The vaccine is made to target unique mutations in…
Sponsor: Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Engineered immune cells take on Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase trial tests a new treatment for people with advanced melanoma or other solid tumors that have spread. Doctors take a patient's own immune cells, modify them in a lab to better recognize and attack cancer, and give them back after a short course of chemotherapy. T…
Phase 1 • Sponsor: Anusha Kalbasi • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New drug cocktail aims to shrink Hard-to-Treat adrenal tumors
Disease control Recruiting nowThis phase II trial is testing whether combining cabozantinib (a drug that blocks tumor growth and blood vessel formation) with pembrolizumab (an immunotherapy that helps the immune system attack cancer) can shrink tumors in people with advanced adrenocortical carcinoma. The stud…
Phase 2 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New hope for rare cancers: immunotherapy drug dostarlimab takes on chemo in phase 2 trial
Disease control Recruiting nowThis phase 2 trial is testing whether the immunotherapy drug dostarlimab can work better than standard chemotherapy as a first treatment for people with rare, advanced cancers that have a specific genetic flaw called dMMR/MSI. The study includes 120 adults with cancers like pancr…
Phase 2 • Sponsor: UNICANCER • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Immunotherapy drug aims to keep adrenocortical cancer at bay
Disease control Recruiting nowThis phase 2 trial is testing whether the immunotherapy drug cemiplimab can delay or prevent cancer progression in people with advanced adrenocortical cancer whose disease has been stabilized by initial chemotherapy. About 31 participants will receive cemiplimab every three weeks…
Phase 2 • Sponsor: Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
New combo therapy aims to tame rare adrenal cancer
Symptom relief Recruiting nowThis study is testing whether a drug called pembrolizumab, given after a special type of radiation, is safe for people with advanced adrenocortical carcinoma that has spread to the liver. The trial will enroll 12 participants and focus on side effects. If successful, it may offer…
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 12:08 UTC
-
New registry aims to unlock secrets of rare adrenal cancer
Knowledge-focused Recruiting nowThis study is a registry that collects information from up to 1,000 people diagnosed with adrenocortical carcinoma, a rare cancer of the adrenal gland. The goal is to gather data on how the disease progresses and how different treatments work, so doctors can better understand the…
Sponsor: University of Wuerzburg • Aim: Knowledge-focused
Last updated Aug 26, 2026 00:00 UTC
-
Hunt for hidden cancer genes: families needed to unlock hereditary secrets
Knowledge-focused Recruiting nowThis study aims to discover new genes that may cause certain cancers to run in families. Researchers will collect blood samples and health information from 1,500 people in families where multiple members have had cancer, especially childhood cancers. The goal is to build a regist…
Sponsor: St. Jude Children's Research Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Scientists investigate adrenal tumors and seek better therapies
Knowledge-focused Recruiting nowThis study aims to learn more about how adrenal tumors form and to test new treatment options for adrenal cancer. Researchers will study up to 500 adults who have an adrenal tumor seen on imaging. The goal is to improve understanding and find better ways to treat these tumors.
Sponsor: University of Wuerzburg • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:30 UTC
-
Rare cancer study aims to unlock secrets of adrenal tumors
Knowledge-focused Recruiting nowThis study looks back at the medical records of 60 adults treated for adrenal cortex carcinoma at a French hospital. Researchers want to learn more about the disease's features and how long patients live after treatment. The goal is to better understand this rare cancer and impro…
Sponsor: University Hospital, Strasbourg, France • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:10 UTC